# A Clinical Trial of SIBP-A16 Injection in Healthy Adults

> **NCT07106918** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 140 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** SIBP-A16 injection
- **BIOLOGICAL:** Nirsevimab
- **OTHER:** SIBP-A16 buffer solution

## Key facts

- **NCT ID:** NCT07106918
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-17
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07106918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07106918, "A Clinical Trial of SIBP-A16 Injection in Healthy Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07106918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*